Ethosuximide

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 1765 publications

Parvalbumin interneuron activation rescues both seizures and impaired social novelty in digenic absence epilepsy mice.

Parvalbumin interneuron activation rescues both seizures and impaired social novelty in digenic absence epilepsy mice.

Journal: Science advances
Published: July 31, 2026

A Micellar Electrokinetic Chromatography Screening Tool for Antiepileptic Drugs.

A Micellar Electrokinetic Chromatography Screening Tool for Antiepileptic Drugs.

Journal: Electrophoresis
Published: May 11, 2026

Electroclinical and behavioral outcomes of add-on ethosuximide in children with developmental and epileptic encephalopathy with spike-wave activation in sleep (D/EE-SWAS): A prospective observational study.

Electroclinical and behavioral outcomes of add-on ethosuximide in children with developmental and epileptic encephalopathy with spike-wave activation in sleep (D/EE-SWAS): A prospective observational study.

Journal: Seizure
Published: May 11, 2026

Thalamic 5-HT2A receptor activation reduces GABA uptake, increases tonic GABAA inhibition and induces absence seizures in Wistar rats.

Thalamic 5-HT2A receptor activation reduces GABA uptake, increases tonic GABAA inhibition and induces absence seizures in Wistar rats.

Journal: Neuropharmacology
Published: May 09, 2026

Antiseizure Medications Impact Mitochondrial Ion Channels via Novel Bioenergetic and Neural Mechanisms.

Antiseizure Medications Impact Mitochondrial Ion Channels via Novel Bioenergetic and Neural Mechanisms.

Journal: Journal of integrative neuroscience
Published: March 27, 2026

Cannabidiol reduces atypical absence seizures and epileptic spasms in a Gabrb3+/D120N mouse model of Lennox-Gastaut syndrome.

Cannabidiol reduces atypical absence seizures and epileptic spasms in a Gabrb3+/D120N mouse model of Lennox-Gastaut syndrome.

Journal: Epilepsia open
Published: March 19, 2026

SLC6A1-Related Neurodevelopmental Disorder: A Scoping Review of Clinical Features and Emerging Therapeutic Strategies.

SLC6A1-Related Neurodevelopmental Disorder: A Scoping Review of Clinical Features and Emerging Therapeutic Strategies.

Journal: Pediatric neurology
Published: March 12, 2026

Neurologists' Views on the Management of Uncontrolled Epilepsy in Spain: A Preliminary Survey.

Neurologists' Views on the Management of Uncontrolled Epilepsy in Spain: A Preliminary Survey.

Journal: Neurology and therapy
Published: February 13, 2026

Interactions between SSR504734, a selective glycine transporter type 1 inhibitor, and antiseizure drugs: pharmacodynamic and pharmacokinetic studies in mice.

Interactions between SSR504734, a selective glycine transporter type 1 inhibitor, and antiseizure drugs: pharmacodynamic and pharmacokinetic studies in mice.

Journal: Neuropharmacology
Published: January 28, 2026

The Cure Better Not Be Worse Than the Illness - Lessons From Ethosuximide in Irritable Bowel Syndrome.

The Cure Better Not Be Worse Than the Illness - Lessons From Ethosuximide in Irritable Bowel Syndrome.

Journal: Gastroenterology
Published: January 20, 2026

Neurotropic potential and docking investigations of newly synthesized triazolopyridine and triazolothienopyridine derivatives.

Neurotropic potential and docking investigations of newly synthesized triazolopyridine and triazolothienopyridine derivatives.

Journal: RSC advances
Published: January 13, 2026

Ethosuximide and Irritable Bowel Syndrome-Related Abdominal Pain: A Randomized Clinical Trial.

Ethosuximide and Irritable Bowel Syndrome-Related Abdominal Pain: A Randomized Clinical Trial.

Journal: JAMA network open
Published: January 08, 2026
Showing 1-12 of 1,765

Last Updated: 09/26/2026